問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Family Medicine

Division of Endocrinology

更新時間：2025-02-26

黃國晉Huang, Kuo-Chin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • im996633@gmail.com

Recruiting Trial

14Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃國晉

List

46Cases

2024-01-01 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2024-01-01 - 2026-12-31

Phase III

Active
A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD

  • Condition/Disease

    Obesity

  • Test Drug

    BI 456906

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2016-11-01 - 2017-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-09-15 - 2025-10-22

Phase III

Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)

  • Condition/Disease

    overweight and obesity

  • Test Drug

    Semaglutide B

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites

2007-11-15 - 2008-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
24Sites

Terminated23Sites

Study ended1Sites

2014-08-15 - 2015-08-15

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助
China Medical University Hospital-Taipei

未分科

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2015-06-01 - 2018-09-30

Phase II

A Phase 2, randomized, multiple-dose, double-blind, placebo-controlled study of JKB-122 in treating subjects with non-alcoholic fatty liver disease (NAFLD)

  • Condition/Disease

    non-alcoholic fatty liver disease (NAFLD)

  • Test Drug

    JKB-122

Participate Sites
7Sites

Terminated7Sites

陳明堯
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

黃怡翔
Taipei Veterans General Hospital

2014-07-01 - 2016-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-06-15 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB